Furthermore, the P2X7-dependent exacerbation of Huntington’s disease symptoms has been observed in murine models, and treatment with brilliant blue G, a P2X7 antagonist, leads to a reduction in the overall pattern of neurodegeneration. Here, P2RX7 is linked to Huntington disease.